Recent News
Read ArticleDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui
Dr. John Cush @RheumNow ( View Tweet)
Ganglion cysts are thin walled cavities contain a viscous, mucinous fluid, arising in proximity to joint capsules/tendon sheaths but do not communicate with the joint. Most common w/ repetitive strain or overuse, trauma, or inflam. arthritis. Steroid injx dont… https://t.co/nUlQvemYa5 https://t.co/gSNzBuPeW4
Dr. John Cush @RheumNow ( View Tweet)
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb
Links:
Dr. John Cush @RheumNow ( View Tweet)
Full read review on the detection & management of #ILD in Autoimmune Dz (AID).
- AID at risk for ILD should be screened with hi-res CT Scan
- ILD should be monitored closely w/ PFTs
- Multidisciplinary Rx includes immunosuppressives & antifibrotics https://t.co/X6Feor2wF5 https://t.co/Z2WBWL3q1W
Dr. John Cush @RheumNow ( View Tweet)
NEW ONLINE POSTER: Safety of a JAKi presented at EULAR 2024!
View safety across 15,000 patient-years of data from 11 Phase 3 trials, including adult patients with RA, PsA, AS, and nr-axSpA. This poster is sponsored by AbbVie US Medical Affairs.
https://t.co/s8D2GwAy52 https://t.co/asQh1D1QQn
Dr. John Cush @RheumNow ( View Tweet)
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Links:
Dr. John Cush @RheumNow ( View Tweet)
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
https://t.co/MYYBBIIuDA https://t.co/1AfbxCuGIq
Dr. John Cush @RheumNow ( View Tweet)
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush @RheumNow ( View Tweet)
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. John Cush @RheumNow ( View Tweet)
Trends in DMARD Use in Juvenile Arthritis 2001-2022
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use. Adalimumab is most used b/tsDMARD after csDMARDs.
Myelitis Associated With Rheumatologic Dz studied in 41 pts (age 44yrs; 95%women). Dx: SLE (41%), Sjogrens (24%), UCTD (15%), Overlap (12%) w/ APL syndr. Half Dx were AQP4-IgG Ab+ (90% w/ extensive cord lesions), 7% MOGAD Ab+, 44% "double-seronegative" myelitis.… https://t.co/VXeHtOlft6 https://t.co/euPjdbYN9j
Dr. John Cush @RheumNow ( View Tweet)
Relapse of idiopathic inflammatory myopathies (IIMs) was seen 65/105 (62%) pts. Higher risk seen w/ ANA positivity (HR 1.13), w/ + histopathology on muscle Bx (HR 1.69), & immunosuppressants use before relapse (HR 0.50). https://t.co/tr0OdvOAPK https://t.co/H3t3u1mDtd
Dr. John Cush @RheumNow ( View Tweet)
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA). This intra-articular formulation is… https://t.co/TSeqNVysjb https://t.co/0OVCobGqsp
Dr. John Cush @RheumNow ( View Tweet)
Predictors of Adverse Pregnancy Outcomes in Lupus
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before… https://t.co/31dqOyD3ZR https://t.co/L9LMn2CPYS
Dr. John Cush @RheumNow ( View Tweet)
Calcium pyrophosphate deposition disease -- a full access, full read review in Lancet Rheumatology. Just published ahttps://buff.ly/4fhtK5q https://t.co/BIdit3OSPu
Dr. John Cush @RheumNow ( View Tweet)
Nailfold videocapillaroscopy (NVC) study of 65 Behcets pts found vascular abnl in 40-47% ( enlarged/tortuous capillaries, microhaemorrhages. Having ≥2 NVC abnormalities increase risk of Vascular events (VTE, superficial thrombophlebitis), but not ANA https://t.co/0KTwA8jIOD https://t.co/q6uc5VhfnT
Dr. John Cush @RheumNow ( View Tweet)
Potential OA Treatment - Chemokine CCL17 Inhibition
MedPage Today
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
Read Article
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5
Links:
Dr. John Cush @RheumNow ( View Tweet)
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq
Dr. John Cush @RheumNow ( View Tweet)
Anxiety and Depression Rising in Rheumatoid Arthritis
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
https://t.co/sWawAgDgyS https://t.co/dVTb7QMFNj
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Blue Collar Arthritis (10.25.2024)-
EMJ Podcast Interview With Dr. Jack Cush
-
ANA+ Consult (10.18.2024)
-
Dot The I, Cross The T (10.11.2024)
Therapeutic Updates
RA Risk Radar: Heart Disease, Infection, and Malignancy
Sponsored by AbbVie Medical Affairs
Listen as rheumatologists Dr. Jeffery Curtis and Dr. Jon Giles review comorbidities that can occur as a consequence of uncontrolled, or under-controlled, inflammation in rheumatoid arthritis. In this conversation they share their clinical expertise on a range of topics, including risk assessment, risk management, and the importance of disease control.
Read Post
A review of two physician case reports. These cases are patients who presented with severe active manifestations of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Read Post
Poster Hall
